Tango Therapeutics (TNGX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$55.3M

Net income growth (year over year)

−42.44%

Net margin

—

Return on equity

−21.34%

EPS (trailing twelve months)

−$0.84

Book value per share

$6.08

P/E (trailing twelve months)

—

Price to book

3.98

Debt to assets

4.60%

Payout ratio

—

Dividend yield

—

Company profile

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

• How do I buy stock in Tango Therapeutics (TNGX)?

  TNGX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.